News & Updates

Show Multimedia Only
Early vedolizumab treatment uncommon in IBD

Early vedolizumab treatment uncommon in IBD

17 Dec 2021 byRoshini Claire Anthony

In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.

Early vedolizumab treatment uncommon in IBD

17 Dec 2021
Remote management during chemotherapy fails to reduce ED visits, hospitalization

Remote management during chemotherapy fails to reduce ED visits, hospitalization

17 Dec 2021
Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults

Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults

17 Dec 2021

Patients with venous thromboembolism (VTE) who are new users of apixaban are less likely to experience recurrent VTE and bleeding than new users of rivaroxaban, a study has shown.

Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults

17 Dec 2021